Globus Medical Q2 FY26 GAAP diluted EPS drops 26.2% to $1.10; net sales rise 5.9% to $789.6 million

• Globus Medical Q2 GAAP diluted EPS fell 26.2% to USD 1.10 as net sales rose 5.9% to USD 789.6 million.
• GAAP net income dropped 25.3% to USD 151.6 million, primarily due to the prior-year Nevro bargain purchase gain.
• Non-GAAP diluted EPS more than doubled to USD 1.34; management cited broad-based share gains, led by US Spine growth.
• Full-year revenue guidance was reaffirmed at USD 3.18 billion-USD 3.22 billion; non-GAAP EPS outlook was raised to USD 4.95-USD 5.05.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Globus Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061615PRIMZONEFULLFEED9805487) on August 06, 2026, and is solely responsible for the information contained therein.